There are several early-stage innovative technologies in development that are aimed to meet the cell supply problem faced by regenerative medicine. All are based on the unique biological properties of stem cells.These technologies employ unipotent and multipotent tissue-specific distributed stem cells.Past advances in technologies for biopharmaceutical manufacturing included effective methods for large-scale production of mammalian cell lines used to produce therapeutic biomolecules and vaccines. However, in these conventional processes, the cells are a waste product that is discarded. Bridging the technological gap between early-stage innovations like SACK, for producing normal human cells on-demand, and the technological need of regenerative medicine for routine supply of normal human cells will require a new type of technological development that produces normal human cells â stem and/or mature â as the desired product. (James L Sherley, Accelerating Progress in Regenerative Medicine by Advancing Distributed Stem Cell-based Normal Human Cell Biomanufacturing)
The aim of the OMICS Journal focuses on specific research discipline, contributing resourceful and impactful platform to embrace the developments in research with technology. OMICS International has been successful in making its spot in scientific community with 700+ peer-reviewed journals with the support of 50,000+ editorial board members, publishing more than 13000 articles in a year which are accessible to more than 100000 scholars worldwide through World Wide Web. It is also a leading scientific event organizer, organizes over 3000+ International Scientific Conferences all over the world annually with the support from 1000+ Scientific associations.
Last date updated on June, 2021